Modeling of miRNA and drug action in the EGFR signaling pathway

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Li, Jian ^a   Pandey, Vikash ^a   Kessler, Thomas ^a   Lehrach, Hans ^a   Wierling, Christoph ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; CASPASE 9; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; MICRORNA; MICRORNA 181C; MICRORNA 192; MICRORNA 34A; MICRORNA 489; MICRORNA INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; NUCLEAR RECEPTOR NUR77; OLIGONUCLEOTIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN AP 1; PROTEIN BAD; PROTEIN CHUK; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; PROTEIN RPS6KB2; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR FOXO; TUBERIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; BIOLOGICAL MODEL; COMPUTER MODEL; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; MATHEMATICAL MODEL; MICRORNA GENE; PROTEIN DEPHOSPHORYLATION; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; ANIMAL; COMPUTER SIMULATION; DRUG EFFECT; GENETICS; HUMAN; KINETICS; METABOLISM;

EUKARYOTA;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; HUMANS; KINETICS; MICRORNAS; MODELS, BIOLOGICAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84855703842     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030140     Document Type: Article

References (78)

1. Cho WC, (2007) OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer 6: 60.
2. Esquela-Kerscher A, Slack FJ, (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
3. Voorhoeve PM, Agami R, (2007) Classifying microRNAs in cancer: The good, the bad and the ugly. Biochim Biophys Acta 1775: 274-282.
4. Bueno MJ, de Castro IP, Malumbres M, (2008) Control of cell proliferation pathways by microRNAs. Cell Cycle 7: 3143-3148.
5. Hwang HW, Mendell JT, (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94: 776-780.
6. Wang Y, Blelloch R, (2009) Cell cycle regulation by microRNAs in embryonic stem cells. Cancer Res 69: 4093-4096.
7. Zhang B, Pan X, Cobb GP, Anderson TA, (2007a) MicroRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12.
8. Zhang BH, Wang QL, Pan XP, (2007b) MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol 210: 279-289.
9. Zhang BH, Farwell MA, (2008) A new emerging class of player for disease diagnostics and gene therapy. J Cell Mol Med 12: 3-21.
10. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
11. Lytle RJ, Yario TA, Steitz JA, (2007) Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. PNAS 104: 9667-9672.
12. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, et al. (2010) Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21. Cancer Cell 18: 282-293.
13. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosine, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
14. Chiocca EA, Lawler SE, (2010) The Many Functions of MicroRNAs in Glioblastoma. World Neurosurgery 73 (6): 598-60.
15. Hanahan D, Weinberg RA, (2011) Hallmarks of Cancer: The Next Generation. Cell 144 (5): 646-74.
16. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, et al. (2008) Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7. J Biol Chem 284 (9): 5731-41.
17. Blume-Jensen P, Hunter T, (2001) Oncogenic kinase signalling. Nature 411: 355-365.
18. Chen X, Yeung TK, Wang Z, (2000) Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res 277: 757-763.
19. Longley DB, Johnston PG, (2005) Molecular mechanisms of drug resistance. J Pathol 205: 275-292.
20. Gross ME, Shazer RL, Agus DB, (2004) Targeting the HER-kinase axis in cancer. Semin Oncol 31: 9-20.
21. Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, et al. (2003) Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23: 3639-3650.
22. Wurdinger T, Costa F, (2007) Molecular therapy in the microRNA era. The Pharmacogenomics Journal 7: 297-304.
23. Wierling C, Herwig R, Lehrach H, (2007) Resources, standards and tools for systems biology. Briefings in Functional Genomics and Proteomics 6 (3): 240-251.
24. Klipp E, Liebermeister W, Wierling C, Kowald A, Lehrach H, et al. (2009) System Biology - A Textbook, pp. 68-70 WILEY-VCH, Weinheim, Germany.
25. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ, (2008) miRBase: tools for microRNA genomics. NAR 34 (Database Issue): D140-D144.
26. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, et al. (2006) The colorectal microRNAome. Proc Natl Acad Sci U S A 103 (10): 3687-92.
27. Clague J, Lippman SM, Yang H, Hildebrandt MA, Ye Y, et al. (2010) Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog 49 (2): 183-9.
28. Ye Y, Wang KK, Gu J, Yang H, Lin J, et al. (2008) Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res(Phila) 1 (6): 460-469.
29. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, et al. (2003) The systems biology makeup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19 (4): 524-531.
30. Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, et al. (2010) EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Science Signaling 3 (124).
31. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, et al. (2008) p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68 (24): 10094-104.
32. Yantiss RK, Goodarzi M, Zhou XK, Rennert H, Pirog EC, et al. (2009) Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol 33 (4): 572-82.
33. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, et al. (2008) Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 68 (24): 10105-12.
34. Kato M, Putta S, Wang M, Yuan H, Lanting L, et al. (2009) TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 11 (7): 881-9.
35. Liang Y, Ridzon D, Wong L, Chen C, (2007) Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 8: 166.
36. Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, et al. (2010) Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 220 (1): 58-70.
37. Chen CZ, (2005) MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353: 1768-1771.
38. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 10: 11.
39. Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, et al. (2009) The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31 (2): 220-31.
40. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, et al. (2008) Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 14 (9): 2588-92.
41. Raser J, Shea E, (2010) Noise in Gene Expression: Origins, Consequences, and Control. Science 309: 2010-2013.
42. Shi M, Liu D, Duan HJ, Shen BF, Guo N, (2010) Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev 29 (4): 785-799.
43. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
44. Orom UA, Kauppinen S, Lund AH, (2006) LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372: 137-141.
45. Vester B, Wengel J, (2004) LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43: 13233-13241.
46. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283 (44): 29897-903.
47. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, et al. (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107 (1): 264-9.
48. Li N, Fu H, Tie Y, Hu Z, Kong W, et al. (2009) miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275 (1): 44-53.
49. Asslaber D, Piňón JD, Seyfried I, Desch P, Stöcher M, et al. (2010) microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 115 (21): 4191-7.
50. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, et al. (2008) Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68 (9): 3193-203.
51. Markey M, Berberich SJ, (2008) Full-length hdmX transcripts decrease following genotoxic stress. Oncogene 27 (52): 6657-66.
52. Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, et al. (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114 (13): 2589-97.
53. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, et al. (2009) Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34 (6): 1395-405.
54. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, et al. (2010) p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 17 (2): 236-45.
55. Chan JA, Krichevsky AM, Kosik KS, (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033.
56. Tong AW, Nemunaitis J, (2008) Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Therapy 15: 341-355.
57. Iguchi H, Kosaka N, Ochiya T, (2010) Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers. Current Drug Discovery Technologies 7: 95-105.
58. Iravani M, Dhat R, Price C, (1997) Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. Oncogene 15: 2609-2614.
59. Hemmati PG, Müer A, Gillissen B, Overkamp T, Milojkovic A, et al. (2010) Systematic genetic dissection of p14ARF-mediated mitochondrial cell death signaling reveals a key role for p21CDKN1 and the BH3-only protein Puma/bbc3. J Mol Med (Berl) 88 (6): 609-22.
60. Mei M, Ren Y, Zhou X, Yuan XB, Han L, et al. (2010) Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 9 (1): 77-86.
61. Shu M, Zheng X, Wu S, Lu H, Leng T, et al. (2011) Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer 10: 59.
62. Stinson S, Lackner M, Adai A, Yu N, Kim HJ, et al. (2011) TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Science Signaling 4: pt5.
63. William M, Merritt MD, Yvonne G, Lin MD, et al. (2008) Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. N Engl J Med 359 (25): 2641-50.
64. Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, et al. (2009) Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. British Journal of Cancer 101 (4): 673-683.
65. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. The New England Journal of Medicine 359 (25): 2641-2650.
66. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, et al. (2009) Dicer1 functions as a haploinsufficient tumor suppressor. Gene & Development 23 (23): 2700-2704.
67. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435 (7043): 834-838.
68. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T, (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genetics 39 (5): 673-677.
69. Moffat J, Sabatini DM, (2006) Building mammalian signaling pathways with RNAi screens. Nat Rev Mol Cell Biol 7: 177-187.
70. Behlke MA, (2006) Progress towards in vivo use of siRNAs. Mol Ther 13: 644-670.
71. Chung CH, Bernard PS, Perou CM, (2002) Molecular portraits and the family tree of cancer. Nat Genet 32: 16-26.
72. Hoheisel JD, (2006) Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet 7: 200-210.
73. Okamura K, Liu N, Lai EC, (2009) Distinct mechanisms for microRNA strand selection by Drosophila Argonautes. Mol Cell 36: 431-44.
74. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-66.
75. Petri CA, (1962) Kommunikation mit Automaten (PhD Thesis), Institut für Instrumentelle Mathematik, Bonn, Germany.
76. Bernardinello L, de Cindio F, (1992) A Survey of Basic Net Models and Modular Net Classes. Springer Verlag, Berlin, Germany.
77. Murata T, (1988) Petri Nets: Properties, Analysis and Applications. Proceedings of The IEEE 77 (4): 541-580.
78. Markoswski A, Markoswski P, (1990) Conditions for the effectiveness of a preliminary test of variance. The American Statistician 44 (4): 322-326.